Yesterday, Feb. 24, 2016, 77 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $250.66 to $7,618,160.00.

Highlighted Stocks Traded by Insiders:

Gastar Exploration (GST) - FREE Research Report

Global Undervalued Securities Master Fund Lp, who is 10% Owner at Gastar Exploration, sold 50,000 shares at $0.99 on Feb. 24, 2016. Following this transaction, the 10% Owner owned 10.1 million shares meaning that the stake was reduced by 0.49% with the 50,000-share transaction.

The shares most recently traded at $0.67, down $0.32, or 47.18% since the insider transaction. Historical insider transactions for Gastar Exploration go as follows:

  • 4-Week # shares bought: 1.8 million
  • 4-Week # shares sold: 60,000
  • 12-Week # shares bought: 1.8 million
  • 12-Week # shares sold: 60,000
  • 24-Week # shares bought: 1.8 million
  • 24-Week # shares sold: 60,000

The average volume for Gastar Exploration has been 827,500 shares per day over the past 30 days. Gastar Exploration has a market cap of $62.5 million and is part of the basic materials sector and energy industry. Shares are down 51.16% year-to-date as of the close of trading on Wednesday.

Gastar Exploration Inc., an independent energy company, engages in the exploration, development, and production of oil, condensate, natural gas, and natural gas liquids in the United States. Currently, there are 7 analysts who rate Gastar Exploration a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GST - FREE

TheStreet Quant Ratings rates Gastar Exploration as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally high debt management risk, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Gastar Exploration Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 227 shares at $9.65 on Feb. 24, 2016. Following this transaction, the Senior V.P., Research owned 403,368 shares meaning that the stake was reduced by 0.06% with the 227-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 227 shares at $9.65 on Feb. 24, 2016. Following this transaction, the Svp, Cfo owned 140,278 shares meaning that the stake was reduced by 0.16% with the 227-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 329 shares at $9.70 on Feb. 24, 2016. Following this transaction, the Senior VP, Pharmaceutical Scie owned 107,086 shares meaning that the stake was reduced by 0.31% with the 329-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 227 shares at $9.65 on Feb. 24, 2016. Following this transaction, the SVP & General Counsel owned 131,188 shares meaning that the stake was reduced by 0.17% with the 227-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 250 shares at $9.65 on Feb. 24, 2016. Following this transaction, the Senior VP, Development and Chi owned 104,861 shares meaning that the stake was reduced by 0.24% with the 250-share transaction.

The shares most recently traded at $9.24, down $0.41, or 4.44% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,109
  • 12-Week # shares sold: 3,629
  • 24-Week # shares sold: 15,447

The average volume for Momenta Pharmaceuticals has been 741,100 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $663.1 million and is part of the health care sector and drugs industry. Shares are down 38.48% year-to-date as of the close of trading on Wednesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 5 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally disappointing historical performance in the stock itself. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Zendesk (ZEN) - FREE Research Report

McDermott Adrian, who is SVP of Product Development at Zendesk, sold 3,035 shares at $17.14 on Feb. 24, 2016. Following this transaction, the SVP of Product Development owned 85,498 shares meaning that the stake was reduced by 3.43% with the 3,035-share transaction.

The shares most recently traded at $21.23, up $4.09, or 19.27% since the insider transaction. Historical insider transactions for Zendesk go as follows:

  • 4-Week # shares sold: 1,625
  • 12-Week # shares sold: 26,625
  • 24-Week # shares sold: 31,501

The average volume for Zendesk has been 860,400 shares per day over the past 30 days. Zendesk has a market cap of $1.9 billion and is part of the technology sector and computer software & services industry. Shares are down 19.59% year-to-date as of the close of trading on Monday.

Zendesk, Inc., a software development company, provides software as a service customer service platform for organizations. Currently, there are 7 analysts who rate Zendesk a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ZEN - FREE

TheStreet Quant Ratings rates Zendesk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Zendesk Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.